On November 17th, novo-nordisk a/s announced that its glucagon-like peptide-1 receptor agonist (GLP-1RA) weekly preparation semaglutide (brand name: novo YING) used for long-term weight management was officially launched in China, providing a weight loss option for overweight and obese patients in China. Reporters learned that with the official commercialization of novo YING, the first prescription for semaglutide used for weight loss indications will be issued in shanghai next week by public hospitals. Regarding the pricing of novo YING, novo-nordisk a/s responded to reporters: "We have started to apply through the provincial bid network for novo YING, and the sales price will refer to the provincial network price." Previously, the drug novo TAI, a 2nd type diabetes treatment with semaglutide from novo-nordisk a/s, has entered the medical insurance, with a cost of less than 800 Chinese yuan for a 3 ml dose. According to reporters, previously, novo YING has entered the private hospital channel and can be scheduled through internet platforms, with a fee of around 1400 yuan per unit (monthly dosage). Reporters randomly called a certain private hospital outpatient department in shanghai, and the staff said that the drug supply is currently tight, with a new batch arriving next week. Patients need to make appointments, undergo relevant medication indication assessments at the outpatient clinic, and then can purchase the medication after the private hospital issues a prescription. (China Business News)